The incidence and prevalence of systemic hypertension are reaching global epidemic proportions. Despite a diverse pharmacologic armamentarium of agents to treat high blood pressure, suboptimal control remains a significant problem in as many as 43% of patients and this rate has not significantly improved over the past 2 decades. There are a variety of factors contributing to this including patient nonadherence due to complex drug regimens and medication side effects, undertreatment, and treatment resistance. There, thus, remains a need to develop novel agents and approaches to antihypertensive therapy that facilitate attainment of optimal blood pressure levels. This monograph will review a number of new pharmacologic targets and interventions as well as a novel method of drug delivery to patients.
American Heart Association.Heart disease and stroke statistics- 2009 update.
2.
Fields LE, Burt VL, Cutler JA, Hughes J., Roccella EJ, Sorlie P.The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398-404.
3.
Yechiam O., Charles FD, Jeffery PH, Margaret C., Sarah Y.Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007 ; 55(7):1056-1065.
4.
Gu Q., Dillon CF, Burt VL, Gillum RFAssociation of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens. 2010;23(1):38-45.
5.
Black HRTriple fixed-dose combination therapy: back to the past. Hypertension. 2009;54(1):19-22.
6.
Chobanian AV , Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6): 1206-1252.
7.
Munzel T., Gori T.Nebivolol: the somewhat-different beta-adrenergic receptor blocker . J Am Coll Cardiol. 2009;54(16): 1491-1499.
8.
Manrique C., Giles TD, Ferdinand KC, Sowers JRRealities of newer beta-blockers for the management of hypertension . J Clin Hypertens (Greenwich). 2009;11(7):369-375.
9.
Nebivolol (Bystolic) for hypertension. Med Lett Drugs Ther. 2008;50(1281):17-19.
10.
Mason RP, Giles TD, Sowers JREvolving mechanisms of action of beta blockers: focus on nebivolol . J Cardiovasc Pharmacol. 2009;54(2):123-128.
11.
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225.
12.
Weiss RJ, Weber MA, Carr AA, Sullivan WAA randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) . 2007;9(9):667-676.
13.
Saunders E. , Smith WB, DeSalvo KB, Sullivan WAThe efficacy and tolerability of nebivolol in hypertensive African American patientsJ Clin Hypertens (Greenwich). 2007;9(11):866-875.
14.
Van Nueten L., Taylor FR, Robertson JINebivolol vs atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens . 1998;12(2):135-140.
15.
Czuriga I., Riecansky I., Bodnar J., et al, For The NEBIS Investigators; NEBIS Investigators Group. Comparison of the new cardio-selective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257-263.
16.
Van Nueten L., Schelling A., Vertommen C., Dupont AG, Robertson JINebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens. 1997;11(12):813-819.
17.
Van Bortel LM, Bulpitt CJ, Fici F.Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005; 18(8):1060-1066.
18.
Rosei EA, Rizzoni D., Comini S., Boari G.Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003 :1:30-35.
19.
Van Nueten L., Lacourciere Y., Vyssoulis G., et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5(4): 237-243.
20.
Papademetriou V.Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol. 2009;103(2): 273-278.
21.
Bangalore S. , Sawhney S., Messerli FHRelation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol . 2008;52(18):1482-1489.
22.
Lavie CJ, Messerli FH, Milani RVBeta-blockers as first-line antihypertensive therapy the crumbling continues . J Am Coll Cardiol. 2009;54(13):1162-1164.
23.
Dockery BK, Bisognano JDDirect renin inhibition: an analysis of possible benefits. Curr Hypertens Rep. 2008;10(4): 313-318.
24.
Yusuf S., Teo KK, Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-1559.
25.
Rongen GA, Lenders JW, Smits P., Thien T.Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet. 1995; 29(1):6-14.
26.
Staessen JA , Li Y., Richart T.Oral renin inhibitors . Lancet . 2006; 368(9545):1449-1456.
27.
Rahuel J., Rasetti V., Maibaum J., et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7(7):493-504.
28.
Stanton A., Jensen C., Nussberger J., O’Brien E.Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42(6):1137-1143.
29.
Vaidyanathan S., Camenisch G., Schuetz H., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren . J Clin Pharmacol. 2008;48(11):1323-1338.
30.
Aliskiren for hypertension in adults. Drug Ther Bull. 2008;46(10): 73-76.
31.
Brown MJAliskiren. Circulation. 2008;118(7):773-784.
32.
Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y., Bedigian MPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation. 2005; 111(8):1012-1018.
33.
Schmieder RE , Philipp T., Guerediaga J., et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation . 2009;119(3):417-425.
34.
Gradman AH, Kad R.Renin inhibition in hypertension. J Am Coll Cardiol . 2008;51(5):519-528.
35.
Solomon SD, Appelbaum E., Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation . 2009; 119(4):530-537.
36.
McInnes GTRenin inhibition: the holy grail of renin-angiotensin system blockade ? J Hum Hypertens. 2007;21(10):766-769.
37.
Jensen C., Herold P., Brunner HRAliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008;7(5): 399-410.
38.
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant . 2009; 24(5):1663-1671.
39.
Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411-415.
40.
Prasad VS, Palaniswamy C., Frishman WHEndothelin as a clinical target in the treatment of systemic hypertension . Cardiol Rev. 2009;17(4):181-191.
41.
Ge Y., Bagnall A., Stricklett PK, Webb D., Kotelevtsev Y., Kohan DECombined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol. 2008;295(6):F1635-F1640.
42.
Krum H., Viskoper RJ, Lacourciere Y., Budde M., Charlon V.The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338(12):784-790.
43.
Enseleit F. , Luscher TF, Ruschitzka F.Darusentan: a new perspective for treatment of resistant hypertension?Expert Opin Investig Drugs. 2008;17(8):1255-1263.
44.
Weber MA, Black H., Bakris G., et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;374(9699):1423-1431.
45.
Gilead Sciences.Second Pivotal Phase III Study of Gilead’s Darusentan for Resistant Hypertension Misses Primary Endpoints [press release]. http://www.gilead.com/pr_1365747 . Accessed February 25, 2010.
46.
Dive V., Chang CF, Yiotakis A., Sturrock EDInhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality?Curr Pharm Des. 2009 ;15(31):3606-3621.
47.
Bevan EG, Connell JM, Doyle J., et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607-613.
48.
Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GADietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.Hypertension. 1991;18(6):798-804.
49.
Daull P., Jeng AY, Battistini B.Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2007;50(3):247-256.
50.
Kostis JB, Packer M., Black HR, Schmieder R., Henry D., Levy E.Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103-111.
51.
Trippodo NC , Robl JA, Asaad MM, Fox M., Panchal BC, Schaeffer TREffects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11(3 pt 1):363-372.
Tabrizchi R.Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs . 2008; 9(3):301-309.
54.
Gu J., Noe A., Chandra P., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptorneprilysin inhibitor (ARNi). J Clin Pharmacol . 2010;50(4): 401-414.
55.
Dickstein K. , De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol . 2004;94(2):237-239.
56.
Heiss G., Wallace R., Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
57.
Drospirenone in HRT?Drug Ther Bull. 2009;47(4):41-44.
58.
Krattenmacher R.Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 ;62(1): 29-38.
59.
White WB, Hanes V., Chauhan V., Pitt B.Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006 ; 48(2):246-253.
60.
White WB, Pitt B., Preston RA, Hanes V.Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension . Circulation. 2005;112(13):1979-1984.
61.
Sica DADrospirenone: an antihypertensive in waiting. Hypertension . 2006;48(2):205-206.
62.
Perreault S. , Lamarre D., Blais L., et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension . Ann Pharmacother. 2005;39(9):1401-1408.
63.
Brown MJSuccess and failure of vaccines against renin-angiotensin system components . Nat Rev Cardiol. 2009;6(10): 639-647.
64.
Brown MJ, Coltart J., Gunewardena K., Ritter JM, Auton TR, Glover JFRandomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) . 2004;107(2):167-173.
65.
Ambuhl PM, Tissot AC, Fulurija A., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens . 2007;25(1):63-72.
66.
Tissot AC, Maurer P., Nussberger J., et al. Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821-827.
67.
Samuelsson O., Herlitz H.Vaccination against high blood pressure: a new strategy. Lancet. 2008;371(9615):788-789.
68.
Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283(14):1829-1836.
69.
Pimenta E., Calhoun DA, Oparil S.Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009;51(5): 371-380.
70.
Peppard PE, Young T., Palta M., Skatrud J.Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378-1384.
71.
Somers VK, White DP, Amin R., et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008;52(8):686-717.
Bradley TD, Floras JSObstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373(9657):82-93.
74.
Esler M., Straznicky N., Eikelis N., Masuo K., Lambert G., Lambert E.Mechanisms of sympathetic activation in obesity-related hypertension . Hypertension. 2006;48(5):787-796.
75.
Norman D., Loredo JS, Nelesen RA, et al. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension . 2006;47(5): 840-845.
76.
Pepperell JC , Ramdassingh-Dow S., Crosthwaite N., et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized parallel trial. Lancet. 2002;359(9302):204-210.
77.
Becker HF, Jerrentrup A., Ploch T., et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003; 107(1):68-73.
78.
Logan AG, Tkacova R., Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J. 2003;21(2):241-247.
79.
Doumas M., Guo D., Papademetriou V.Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opin Ther Targets . 2009;13(4): 413-425.
80.
CVRx.For Medical Professionals-Products . http://www.cvrx.com/medpros/index.php?id=15 . Accessed February 25, 2010.
81.
National Institutes of Health.Device Based Therapy in Hypertension Extension Trial (DEBuT-HET). http://clinicaltrials.gov/ct2/show/NCT00710294. Accessed February 25, 2010.
82.
Wustmann K. , Kucera JP, Scheffers I., et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension . 2009;54(3):530-536.
83.
Schlaich MP , Sobotka PA, Krum H., Whitbourn R., Walton A., Esler MDRenal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195-1201.
84.
Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373(9671):1275-1281.
85.
DiBona GF, Kopp UCNeural control of renal function . Physiol Rev. 1997;77(1):75-197.
86.
DiBona GFThe sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43(2):147-150.
87.
Doumas M., Douma S.Interventional management of resistant hypertension. Lancet . 2009;373(9671):1228-1230.
88.
Hypertension: uncontrolled and conquering the world. Lancet. 2007;370(9587):539-539.
